Open AccessCLINICAL CASES OF THE EFFICACY OF THERAPY MULTIKINASE INHIBITORS OF METASTATIC RADIOID-REFRACTORY DIFFERENTIATED THYROID CANCER
Author(s) -
A. Polyakov,
A.V. Mordovsky,
П. А. Никифорович,
M. Ratushnyy,
И.В. Новикова,
Anna V. Boyko,
L. V. Bolotina,
Artem R. Gevorcov
Publication year - 2018
Publication title -
èndokrinnaâ hirurgiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-3965
pISSN - 2306-3513
DOI - 10.14341/serg9614
Subject(s) - sorafenib , medicine , refractory (planetary science) , thyroid cancer , targeted therapy , oncology , cancer , drug , pharmacology , physics , astrobiology , hepatocellular carcinoma
Well differentiated thyroid cancer (WDTC) is referred to non-aggressive tumors with a relatively favorable course. However, in 10% of cases, distant metastases are recorded in this pathology, of them 5–15% of cases develop refractoriness to I131 therapy. Resistance to radioactive iodine therapy in patients with WDTC significantly worsens the overall and disease-free survival. In 2014, the targeted drug Sorafenib was registered in our country, as the first drug of choice for the treatment of patients with metastatic radio-refractory WDTC. The article presents his own experience in the therapy of radiorefractory thyroid cancer with a multikinase inhibitor – Sorafenib. This drug is effective for the treatment of this cohort of patients and also helps to maintain a satisfactory quality of life. Therapy with a multikinase inhibitor statistically significantly increases the time to progression and the median time without progression. In this way, patients have been monitored for a process that would not have been possible to achieve without the use of a targeted drug with multikinase inhibition.